还原型谷胱甘肽辅助治疗对狼疮肾炎患者肾小球系膜细胞CXCL9/10/11表达的影响
|
摘要
目的分析还原型谷胱甘肽辅助治疗对狼疮肾炎患者肾小球系膜细胞CXCL9/10/11表达的影响。方法选择本院2014年7月至2016年7月收治的64例临床确诊的狼疮肾炎患者为研究对象,按照患者入院顺序随机分为常规治疗组和联合治疗组,每组各32例。常规治疗组患者给予醋酸泼尼松和霉酚酸酯治疗,联合治疗组患者在常规治疗基础上加用还原型谷胱甘肽治疗。对比分析治疗前后两组患者血肌酐(Scr)、血尿素氮(BUN),补体C3、C4水平,24小时尿蛋白量,趋化因子CXCL9、CXCL10、CXCL11在血清和肾小球系膜细胞中的表达水平。结果治疗后,联合治疗组患者Scr、BUN及尿蛋白水平均显著低于常规治疗组(P<0.05);C3、C4水平均显著高于常规治疗组(P<0.05)。联合治疗组患者CXCL9、CXCL10、CXCL11在血清和肾小球系膜细胞中的表达水平均显著低于常规治疗组(P<0.01)。结论在常规治疗基础上增加还原型谷胱甘肽治疗,能够显著减轻狼疮肾炎患者的肾损伤,改善患者肾功能。
Objective To analyze the effect of Glutathione on the expression of CXCL9/10/11 in glomerular mesangial cells of patients with lupus nephritis. Method 64 patients with lupus nephritis from July 2014 to July 2016 in our hospital were collected in our study, according to the order of admission patients were randomly divided into conventional treatment group and combined treatment group. Conventional treatment group patients were given prednisone and mycophenolate mofetil treatment, and combined treatment group patients were increased Glutathione on the basis of conventional treatment. The serum creatinine(Scr), blood urea nitrogen(BUN), complement C3 and C4 levels, 24 hour urine protein, chemokine CXCL9, CXCL10 and CXCL11 expression levels in serum and glomerular mesangial cells of the two groups before and after treatment were compared. Result After treatment, the levels of Scr, BUN and urine protein in combined treatment group were significantly lower than those in conventional treatment group(P < 0.05), C3 and C4 levels were significantly higher than those in conventional treatment group(P < 0.05). The expression levels of CXCL9, CXCL10 and CXCL11 in the serum and glomerular mesangial cells in combined treatment group were significantly lower than those in conventional treatment group(P < 0.01). Conclusion The treatment of Glutathione on the basis of conventional treatment can significantly reduce the renal injury in patients with lupus nephritis and improve the renal function of patients.
Objective To analyze the effect of Glutathione on the expression of CXCL9/10/11 in glomerular mesangial cells of patients with lupus nephritis. Method 64 patients with lupus nephritis from July 2014 to July 2016 in our hospital were collected in our study, according to the order of admission patients were randomly divided into conventional treatment group and combined treatment group. Conventional treatment group patients were given prednisone and mycophenolate mofetil treatment, and combined treatment group patients were increased Glutathione on the basis of conventional treatment. The serum creatinine(Scr), blood urea nitrogen(BUN), complement C3 and C4 levels, 24 hour urine protein, chemokine CXCL9, CXCL10 and CXCL11 expression levels in serum and glomerular mesangial cells of the two groups before and after treatment were compared. Result After treatment, the levels of Scr, BUN and urine protein in combined treatment group were significantly lower than those in conventional treatment group(P < 0.05), C3 and C4 levels were significantly higher than those in conventional treatment group(P < 0.05). The expression levels of CXCL9, CXCL10 and CXCL11 in the serum and glomerular mesangial cells in combined treatment group were significantly lower than those in conventional treatment group(P < 0.01). Conclusion The treatment of Glutathione on the basis of conventional treatment can significantly reduce the renal injury in patients with lupus nephritis and improve the renal function of patients.
引文
[1]符勇,肖湘云,唐虹.狼疮肾炎患者治疗方案与病理分型关系的探讨[J].当代医学,2013,19(10):33-35.
[2]王万鹏,张敏芳,王玲,等.狼疮肾炎患者循环mi RNA表达谱研究及循环mi RNA-130b-3p的临床意义[J].中华肾病研究电子杂志,2015,4(6):26-32.
[3]施栋梁,祝先进,林秋萍,等.雷公藤内酯醇抑制小鼠肾小球系膜细胞表达CXCL10的实验研究[J].实验与检验医学,2016,34(3):267-270.
[4]郑敬民,尹广,恽时锋,等.狼疮性肾炎肾组织肥大细胞检测分析研究[J].医学研究生学报,2014,27(5):497-501.
[5]张北平,刘树锋,王海,等.GSH对于系统性红斑狼疮治疗观察[J].中国现代药物应用,2016,10(13):189-190.
[6]谢雅清,梁晓美,叶伟霞.还原型谷胱甘肽的药理作用与临床应用研究进展[J].中国药业,2013,22(7):124-127.
[7]岳颖,纪岩文,张勉之,等.补肾活血方对肝肾阴虚型红斑狼疮肾炎患者疗效及免疫功能影响[J].天津中医药大学学报,2015,34(6):328-331.
[8]刘斌.来氟米特治疗狼疮肾炎临床观察[J].当代医学,2015,21(12):117-118.
[9]夏琼.CXCL16及CXCL10在狼疮性肾炎患者中的表达及与疾病活动的相关性[D].合肥:安徽医科大学,2014.
[10]何盾,李赛英,张顺,等.系统性红斑狼疮患者合并狼疮肾炎高危因素分析[J].中国现代医学杂志,2012,22(9):65-67.
[11]Mok CC,Yap DY,Navarra SV,et al.Overview of lupus nephritis management guidelines and perspective from Asia[J].Nephrology(Carlton),2014,19(1):11-20.
[12]晁杨,彭清莲,马杰,等.狼疮性肾炎的治疗[J].长春中医药大学学报,2015,31(1):189-191.
[13]杨大东.系统性红斑狼疮患者血液系统损害特点及其临床意义[J].中国医学前沿杂志(电子版),2015,7(5):100-102.
[14]Griffith JW,Sokol CL,Luster AD.Chemokines and chemokine receptors:positioning cells for host defense and immunity[J].Annu Rev Immunol,2014,32:659-702.
[15]Palomino DC,Marti LC.Chemokines and immunity[J].Einstein(Sao Paulo),2015,13(3):469-473.
[16]施栋梁,林青.趋化因子CXCL9、CXCL10、CXCL11与狼疮肾炎相关性研究进展[J].免疫学杂志,2016,32(7):630-633.
[17]蒋春萍,王强,罗光成,等.调节性T细胞趋化因子受体表达与系统性红斑狼疮相关性研究进展[J].中华风湿病学杂志,2017,21(3):195-198.
[18]林秋萍,祝先进,黄丽华,等.IFN-γ上调人肾小球系膜细胞CXCL9、CXCL10和CXCL11表达的实验研究[J].福建医药杂志,2015,37(6):85-88.
[19]廖永强,夏洪娇,彭可君,等.氧化还原态改变和淋巴细胞凋亡与系统性红斑狼疮疾病活动度的相关性研究[J].中国免疫学杂志,2013,29(12):1288-1292.
[20]李鞠,唐凤英.基于超高效液相色谱-质谱的狼疮肾炎血清代谢组学研究[J].中华风湿病学杂志,2016,20(12):817-821.
[2]王万鹏,张敏芳,王玲,等.狼疮肾炎患者循环mi RNA表达谱研究及循环mi RNA-130b-3p的临床意义[J].中华肾病研究电子杂志,2015,4(6):26-32.
[3]施栋梁,祝先进,林秋萍,等.雷公藤内酯醇抑制小鼠肾小球系膜细胞表达CXCL10的实验研究[J].实验与检验医学,2016,34(3):267-270.
[4]郑敬民,尹广,恽时锋,等.狼疮性肾炎肾组织肥大细胞检测分析研究[J].医学研究生学报,2014,27(5):497-501.
[5]张北平,刘树锋,王海,等.GSH对于系统性红斑狼疮治疗观察[J].中国现代药物应用,2016,10(13):189-190.
[6]谢雅清,梁晓美,叶伟霞.还原型谷胱甘肽的药理作用与临床应用研究进展[J].中国药业,2013,22(7):124-127.
[7]岳颖,纪岩文,张勉之,等.补肾活血方对肝肾阴虚型红斑狼疮肾炎患者疗效及免疫功能影响[J].天津中医药大学学报,2015,34(6):328-331.
[8]刘斌.来氟米特治疗狼疮肾炎临床观察[J].当代医学,2015,21(12):117-118.
[9]夏琼.CXCL16及CXCL10在狼疮性肾炎患者中的表达及与疾病活动的相关性[D].合肥:安徽医科大学,2014.
[10]何盾,李赛英,张顺,等.系统性红斑狼疮患者合并狼疮肾炎高危因素分析[J].中国现代医学杂志,2012,22(9):65-67.
[11]Mok CC,Yap DY,Navarra SV,et al.Overview of lupus nephritis management guidelines and perspective from Asia[J].Nephrology(Carlton),2014,19(1):11-20.
[12]晁杨,彭清莲,马杰,等.狼疮性肾炎的治疗[J].长春中医药大学学报,2015,31(1):189-191.
[13]杨大东.系统性红斑狼疮患者血液系统损害特点及其临床意义[J].中国医学前沿杂志(电子版),2015,7(5):100-102.
[14]Griffith JW,Sokol CL,Luster AD.Chemokines and chemokine receptors:positioning cells for host defense and immunity[J].Annu Rev Immunol,2014,32:659-702.
[15]Palomino DC,Marti LC.Chemokines and immunity[J].Einstein(Sao Paulo),2015,13(3):469-473.
[16]施栋梁,林青.趋化因子CXCL9、CXCL10、CXCL11与狼疮肾炎相关性研究进展[J].免疫学杂志,2016,32(7):630-633.
[17]蒋春萍,王强,罗光成,等.调节性T细胞趋化因子受体表达与系统性红斑狼疮相关性研究进展[J].中华风湿病学杂志,2017,21(3):195-198.
[18]林秋萍,祝先进,黄丽华,等.IFN-γ上调人肾小球系膜细胞CXCL9、CXCL10和CXCL11表达的实验研究[J].福建医药杂志,2015,37(6):85-88.
[19]廖永强,夏洪娇,彭可君,等.氧化还原态改变和淋巴细胞凋亡与系统性红斑狼疮疾病活动度的相关性研究[J].中国免疫学杂志,2013,29(12):1288-1292.
[20]李鞠,唐凤英.基于超高效液相色谱-质谱的狼疮肾炎血清代谢组学研究[J].中华风湿病学杂志,2016,20(12):817-821.